<DOC>
	<DOCNO>NCT02195986</DOCNO>
	<brief_summary>The purpose study determine therapeutic equivalence Mylan 's estradiol vaginal cream Estrace® cream superiority product placebo . The protocol describe randomize , double-blind , multi-dose , placebo-controlled , parallel study 7 day treatment .</brief_summary>
	<brief_title>A Comparison Estradiol Vaginal Cream Estrace® Cream 350 Postmenopausal Females With Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Capable provide informed consent . 2 . Age : 4070 year old . 3 . Sex : Female 4 . Postmenopausal define least 12 month spontaneous amenorrhea least 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml least 6 week postsurgical bilateral oophorectomy without hysterectomy . 5 . Weight : At least 48 kg subject Body Mass Index less equal 38 kg/m2 great equal 19 kg/m2 . 6 . Baseline evaluation requirement : ≤5 % superficial cell vaginal smear cytology Vaginal pH &gt; 5.0 At least one patient selfassessed moderate severe symptom vulvar and/or vaginal atrophy ( VVA ) follow list identify subject : Vaginal dryness Vaginal and/or vulvar irritation/itching Dysuria Vaginal pain associate sexual activity Vaginal bleeding associate sexual activity ( absence vs. presence ) 7 . All subject judge eligible participation study principal subinvestigator physician prestudy medical evaluation perform within 28 day initial dose study medication include : 1. normal nonclinically significant physical examination , include vital sign 2. normal nonclinically significant pelvic examination consistent hypoestrogenemia 3. normal nonclinically significant breast exam mammogram 4. normal nonclinically significant ASCUS Papanicolaou ( `` Pap '' ) smear negative HPV subject intact uterus cervix 5. within normal limit nonclinically significant laboratory evaluation result ( unless otherwise note exclusion criterion ) follow test : Serum Chemistry Hematology Coagulogram Urinalysis 6. normal nonclinically significant 12 Lead ECG . 7. negative urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , methadone phencyclidine follow exception : positive test amphetamine , barbiturate , benzodiazepine , opiate may allow provide subject valid prescription stable regimen complies Exclusion Criteria , Section 6.3.2 . 8. negative urine cotinine test . 8 . For woman intact uterus , endometrial thickness &lt; 5 mm determine vaginal ultrasonography . 9 . If warrant , test examination may perform discretion Principal Investigator responsible physician . 10 . Ability use applicator properly . 1 . Institutionalized subject use . 2 . Any contraindication estrogen therapy . 3 . Social Habits : 1 . Use tobaccocontaining product within 1 year start study . 2 . Regular intake 7 unit alcohol per week . 3 . Beginning new regimen vitamin herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . History drug and/or alcohol abuse within one year start study . 4 . Medications : 1 . Use new prescription overthecounter ( OTC ) medication regimen within fourteen ( 14 ) day prior initial dose study medication ( necessary medication , unless otherwise note exclusion criterion , dose stabilized period least 14 day prior initial dose study drug expect remain stable entire study period allow , exception acetaminophen , may administer needed treat minor adverse event ) . 2 . Use hormonal replacement therapy follow time period : within 2 week baseline assessment vaginal therapy ( ring , cream , gel ) within 4 week baseline assessment transdermal estrogen alone estrogen/progestin therapy within 8 week baseline assessment oral estrogen and/or progestin therapy intrauterine progestin therapy within 3 month baseline assessment progestin implant estrogen alone injectable therapy within 6 month baseline assessment estrogen pellet progestin injectable therapy 3 . A depot injection implant drug within 3 month prior administration study medication . 4 . Currently take medication indicate anticoagulation result exclude condition list # 5 . This include limited warfarin , heparin , NSAIDs , clopidogrel , dabigatran , etc . 5 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychological , urinary , musculoskeletal disease malignancy unless medical control and/or deem clinically significant Principal Investigator Medical Subinvestigator . 2 . Manifestation treatment significant cardiovascular disease ( congestive heart failure , stroke ischemic attack , myocardial infarction , coronary artery bypass , percutaneous angioplasty &gt; 50 % angiographic narrowing coronary artery , thrombosis deep vein artery , thromboembolic disorder , pulmonary embolism ) history condition . 3 . Coronary artery cerebrovascular disease . 4 . Current clinically significant liver kidney dysfunction/disorders . 5 . Current clinically significant gallbladder dysfunction/disorders . 6 . Abnormal clinically significant breast examination . Acceptable breast examination define mass finding identify suspicious malignancy . 7 . First degree family history breast cancer . 8 . Current non diet control diabetes mellitus clinically significant endocrinological disease . 9 . Estrogendependent neoplasia 10 . Postmenopausal uterine bleed 11 . Endometrial hyperplasia 12 . Uncontrolled hypothyroidism 13 . Urinalysis show ongoing clinically significant urinary tract infection require treatment . 14 . Current clinically significant vaginal infection require treatment . 15 . Known chronic lichen sclerosis 16 . Acute illness time either prestudy medical evaluation dosing . 17 . History allergy hypersensitivity estradiol , related product , inactive ingredient . 18 . Undiagnosed vaginal bleeding history significant risk factor endometrial cancer . 19 . Increased frequency severity headaches previous hormone estrogen therapy . 20 . History psychiatric disorder occur within last 6 month require hospitalization medication . 21 . Current hypercalcemia , hypocalcemia , and/or hypertriglyceridemia . 22 . Clinically significant eye/visual abnormality retinal vascular thrombosis , partial complete loss vision , proptosis , diplopia , papilledema , retinal vascular lesion . 6 . Any reason , opinion Principal Investigator Medical SubInvestigator , would prevent subject safely participate study . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Sitting blood pressure high 150/90 mmHg screen . 9 . Baseline serum estradiol level &gt; 30 pg/mL screening .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>vaginal dryness</keyword>
	<keyword>vaginal and/or vulvar irritation/itching</keyword>
	<keyword>dysuria</keyword>
	<keyword>vaginal pain bleeding associate sexual activity</keyword>
	<keyword>vaginal atrophy</keyword>
</DOC>